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Small diameter arterial bypass grafts are considered as unmet clinical need since
the current grafts have poor patency of 25% within 5 years. We have developed
a 3D scaffold manufactured from natural and synthetic biodegradable polymers,
poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and poly(ε-caprolactone) (PCL),
respectively. Further to improve the biophysical properties as well as endothelialisation,
the grafts were covalently conjugated with arginine-glycine-aspartic acid (RGD) bioactive
peptides. The biophysical properties as well as endothelialisation of PHBV/PCL and PCL
2 mm diameter bypass grafts were assessed with and without biofunctionalisation with
RGD peptides in vitro and in vivo. Morphology of the grafts was assessed by scanning
electron microscopy, whereas physico-mechanical properties were evaluated using a
physiological circulating system equipped with a state of art ultrasound vascular wall
tracking system. Endothelialisation of the grafts in vitro and in vivo were assessed
using a cell viability assay and rat abdominal aorta replacement model, respectively.
The biofunctionalisation with RGD bioactive peptides decreased mean fiber diameter
and mean pore area in PHBV/PCL grafts; however, this was not the case for PCL grafts.
Both PHBV/PCL and PCL grafts with RGD peptides had lower durability compared to
those without; these durability values were similar to those of internal mammary artery.
Modification of PHBV/PCL and PCL grafts with RGD peptides increased endothelial
cell viability in vitro by a factor of eight and enhanced the formation of an endothelial
cell monolayer in vivo 1 month postimplantation. In conclusion, PHBV/PCL small-caliber
graft can be a suitable 3D scaffold for the development of a tissue engineering arterial
bypass graft.
Keywords: poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(ε-caprolactone), vascular grafts, RGD peptides,
morphology, physico-mechanical properties, endothelialisation, biocompatibility
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INTRODUCTION
Reconstructive surgery is a conventional treatment of coronary
artery disease and peripheral artery disease, and autologous
saphenous vein, internal mammary and radial artery grafts
are commonly used (Taggart, 2013). The problem is that a
significant proportion of the patients does not have suitable
veins or arteries (Desai et al., 2011). Synthetic grafts prepared
from poly(ethylene terephthalate) (PET, Dacron) or expanded
poly(tetrafluoroethylene) (ePTFE, Teflon) were suggested as an
appropriate option (Roll et al., 2008). Nevertheless, these grafts
perform well as large-caliber replacements but their long-term
patency is discouraging in small-caliber applications (<6 mm
diameter) such as coronary, crural, or microvessel surgery
(Chlupác et al., 2009). A reason for this is a low blood flow
resulting in an intimal hyperplasia and/or thrombus formation
at the anastomotic site (Chlupác et al., 2009).
Therefore, tissue engineering of vascular grafts is a promising
approach for the replacement of small-caliber blood vessels
(G et al., 2015). Small-caliber vascular grafts prepared from
biodegradable polymers act as a scaffold for the formation
of a new blood vessel in situ (G et al., 2015). It was
previously demonstrated that poly(ε-caprolactone) (PCL), a
synthetic biodegradable polymer, can be used for the fabrication
of the vascular grafts (de Valence et al., 2012). Poly(3-
hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) is a natural
biodegradable polymer synthesized by bacteria as a storage
compound under growth limiting conditions (Quillaguamán
et al., 2010). One of its monomers, 3-hydroxybutanoic acid, is a
natural metabolite produced in the human body (Quillaguamán
et al., 2010). This ensures a high biocompatibility of PHBV
(Quillaguamán et al., 2010). Earlier studies by our group
revealed that the combination of PHBV with PCL improves
biocompatibility of electrospun small-caliber vascular grafts
(Antonova et al., 2015a,b).
Arginine-glycine-aspartic acid (RGD) is a cell adhesion
motif displayed on many extracellular matrix proteins such
as fibronectin, laminin, vitronectin, fibrinogen, von Willebrand
factor, and osteopontin (Wang et al., 2013). This motif is a crucial
ligand for integrins, receptors responsible for cell attachment,
migration, proliferation, differentiation, and survival (Harburger
and Calderwood, 2009). Therefore, RGD-containing peptides, or
simply RGD peptides, were suggested as a promising agent for
the modification of polymers to improve their biocompatibility,
particularly adhesive properties (Ren et al., 2015). We carried out
this study with the aim to assess whether modification with RGD
peptides affects morphology, physico-mechanical properties, and
biocompatibility of PHBV/PCL and PCL vascular grafts.
MATERIALS AND METHODS
Graft Preparation
Small-caliber vascular grafts were fabricated by electrospinning
(Nanon-01A, MECC) from PCL (80,000 kDa, 14%)/chloroform
or PHBV/PCL (5:10%)/chloroform solutions using the following
respective parameters: 15 or 20 kV voltage, 0.5 or 0.3 mL/h feed
rate, 2 mm rotating drum diameter, 22G needle, and 150 mm tip-
to-collector distance. All reagents unless otherwise stated were
purchased from Sigma–Aldrich.
Polymer Amination-Activation
A 1:1 2-propanol: water solution was used to remove oil and dirt
residues from the polymers, which were then washed thoroughly
with deionised water (Causa et al., 2010). Grafts were treated with
10% ethylenediamine (EDA) – 2-propanol solution at 37◦C for
1 h (Zhang and Hollister, 2009). After treatment, the samples
were rinsed with 0.3% Tween-20 solution in deionised water until
all amination solution was washed away or until the samples sank
in water (Causa et al., 2010). Samples were then air dried.
RGD Peptide Conjugation
For the linker solution, 0.6 mg/mL 1-ethyl-3-(3-dimethyla-
minopropyl) carbodiimide, 0.827 mg/mL N-hydroxysuccini-
mide, and 3.59 mg/mL succinic acid were combined in phosphate
buffered saline (PBS) and roll-mixed for 1 h (Gabriel et al.,
2006). The synthesis of the lauric acid, glycine, arginine,
glycine, aspartic acid, glycine, aminohexanoic acid (LA-GRGDG-
AHex) – RGD containing biomolecule was previously described
in detail (Sedaghati et al., 2014). The peptide was diluted to
the appropriate concentration (0.2 mg/mL) in PBS with 0.05%
Tween-20 (PBST) (Zhang and Hollister, 2009).
Samples were treated with the linker solution for 30 min in the
dark, and after a thorough wash with PBS, they were incubated
with the RGD solution on a shaker for 1 h in the dark (37◦C), and
then were put in the fridge overnight (4◦C). After allowing for the
reaction to proceed, samples were washed thoroughly with PBST,
PBS, and then air dried (Gabriel et al., 2006).
Amino Acid Detection
To identify whether conjugation with RGD peptides was
successful, we performed Orange II staining and ninhydrin test.
For Orange II staining, the polymer samples were immersed in
1.5 mL of Orange II sodium dye solution (Noel et al., 2011).
Briefly, 14 mg/mL of Orange II dye were dissolved in a pH 3
solution of hydrochloric acid (HCl). Incubation for 30 min at
37◦C followed after the samples were immersed in dye solution.
The samples were rinsed well in HCl solution (pH 3) to remove
unbound dye. After drying in air, the samples were immersed in
a 1 mL of sodium hydroxide (NaOH, pH 12) alkaline solution
to free the dye in solution. Absorbance at 480 nm of the dye
containing solution was measured using the multiwell plate
reader in the UCL Division of Surgery and Interventional Science
(Royal Free Hospital, London). For ninhydrin test, each sample
was immersed in a 0.178 mg/mL solution of ninhydrin in ethanol
for 1 min, incubated at 37◦C for 30 min in order to react, and
then 2 mL/sample of tetrahydrofuran was used to dissolve the
samples. To each dissolved sample, 2 mL of 2-propanol was added
and the absorbance of the final solution was measured at 560 nm
(Santiago et al., 2006).
To determine the effect of RGD peptides on polymer
surface, we used Fourier transform infrared spectroscopy (FTIR).
Following the colorimetric test, a more specific analysis of the
FTIR provides information specific for the RGD peptides which is
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further evidence of their covalent immobilization on the polymer.
Measurements were taken twice to confirm that the spectra were
identical for unmodified and aminolysed PHBV/PCL and PCL.
The individual amino acids of the synthesized RGD peptides
were identified by thin layer chromatography (TLC). Sample
tubes were placed in 20.2% w/w HCl acid (concentrated) solution
in sealed autoclave-able containers with enough HCl so as to
just float off the surface. Bottles were placed in the oven (105◦C)
overnight. The sample containing HCl solution was evaporated
off and 100 µL distilled water was added after the containers
cooled down. TLC was performed using F254 silica-gel-on-glass
plates (Merck). A butanol:acetic acid:water 1:1:1 mixture was
used as developing solvent and after 30 min the dried plates were
sprayed with a 0.2% ninhydrin solution to detect the spots. The
process was repeated twice and Rf factors were calculated from
the center of each spot according to the equation:
Rf = Da/Ds,
where Da is the distance traveled by the analyte and Ds is
the distance traveled by the solvent. An arginine/aspartic acid
(1 mg/mL in deionised water) solution was also impregnated into
the plate to compare with the dissolved sample. Reference for Rf
values were taken from the previous study (Sedaghati et al., 2014).
Morphological Assessment
PHBV/PCL and PCL graft samples 0.5 mm × 0.5 mm with
and without RGD peptides (n = 5 per each group) were
examined using scanning electron microscopy (Hitachi S-3400N,
Hitachi) with Au-Pd sputter coating (Quorum Technologies) of
30 nm thickness. Fiber diameter, pore area, and porosity were
measured using ImageJ (National Institutes of Health). Mean
fiber diameter and mean pore area were calculated after at least
100 measurements per each sample.
Evaluation of Physico-Mechanical
Properties
Assessment of durability and elastic deformation properties
was performed using universal testing machine (Zwick/Roell).
Testing was performed with 1 cm working segment length, 0.01 N
preload, and 10 mm/min crosshead speed. Durability, elasticity,
and stiffness were evaluated by yield stress, relative elongation,
and elastic modulus, respectively. We assessed 6 vascular grafts
per each group. An ePTFE graft, human saphenous vein (SV)
and internal mammary artery (IMA) (n = 6 per each) were
used as the controls. SV and IMA were collected from patients
who underwent coronary artery bypass graft surgery, and all the
participants provided written informed consent after receiving a
full explanation of the study. The study protocol was approved by
a local ethical committee.
With the aim to assess compliance, defined as the change in
volume of a structure with respect to the change in pressure, a
flow circuit was set up as shown in Figure 1 in order to perfuse
grafts. This circuit was designed to create arterial pulsatile flow
of physiological pressures and characteristics. A pulsatile blood
pump (Harvard Apparatus) was used to create pulsatile flow,
with a pulse rate of 60 beats per minute. This was connected
by a flexible plastic tubing via the grafts and vessels under
testing to a fluid reservoir (Radnoti Glass Technology), which in
turn was connected back to the pump, thus creating a circuit.
A heat exchanger (Grant Instruments) maintained the fluid
reservoir at 37◦C. The pressure of the circuit was measured
using a pressure transducer (TranStar Pressure Monitoring
System) and pressure monitor (Datex Engstrom, Datex-Ohmeda
Division Instrumentarium), connected to the circuit distal to
the grafts. Pressure was varied by altering the level of the fluid
reservoir above the grafts. Heparinised (Heparin sodium, CP
Pharmaceuticals Ltd., Wrexham, UK) whole human blood mixed
with normal saline (NaCl 0.9%, Baxter Healthcare) in a ratio of
2:1 respectively, was used to perfuse the circuit. For each pint of
blood used, approximately 2 mL (1000 I.U. in 1 mL) of heparin
was added.
Fifty millimeter lengths of two different grafts were used
(n = 6). Grafts were connected one at a time into the flow
circuit and positioned in a bath of normal saline. All conduits
were subjected to 3% longitudinal stretch to reproduce in vivo
characteristics (Sarkar et al., 2007). In order to measure wall
distension due to the pressure in the circuit, a duplex color
flow ultrasound system (Picus, Pie Medical Systems) was used
to obtain real time M-mode images of each segment. A specially
designed supporting frame was used to hold the 10 MHz
linear array probe in the bath directly over the segment,
so reliable readings could be taken. At each mean pressure
wall distension was found from end-diastolic and end-systolic
intraluminal diameters for each segment, determined by a wall-
tracking system (Pie Medical Wall Track Version 2, Pie Medical
Systems). Mean pressures of 30–90 mmHg were used, increasing
at 30 mmHg increments. At each pressure, wall movement was
measured at three sites on each graft for a period of 12 s.
After the collection of data, compliance (C) was calculated
from wall distension and pressure, using the appropriate equation
(Hermeling et al., 2012; Ahmed et al., 2014):
C(%mmHg−1 × 10−2) =
((Ds− Dd)/Dd × 104)/(Ps− Pd),
where P, D, s, and d are pressure, diameter, systole, and diastole
respectively.
At each of the three locations, six measurements of wall
distension were made over the 12 s, and average data were
calculated.
Cell Viability Assay
Human umbilical vein endothelial cells (HUVECs) were
isolated according to adapted protocol of Jaffe et al. (1973).
Cells were cultured using endothelial cell culture medium
kit (BD Bioscience). For the experiments, we used cells
of 5th passage. Briefly, 1.8 mm diameter PHBV/PCL, PCL,
PHBV/PCL/RGD, and PCL/RGD scaffolds (n = 6 per each
group) were fixed at the bottom of the wells of 24-well
plate using 0.6% agarose (Amresco). Cells (2.5*105 cells per
polymer sample) were cultured during 6 days at 37◦C, 5%
CO2, and high humidity (MCO-18AIC, Sanyo). After 6 days
of culture, we stained cells with Hoechst 33342 (2 µg/mL)
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FIGURE 1 | Arterial pulsatile flow circuit. (A) Photograph of the flow circuit apparatus. (B) Detail of the perspex/saline bath and ultrasound probe in flow circuit.
(C) Photograph of the ultrasound machine and wall tracking system. (D) B-mode (top) and M-mode (bottom) ultrasound images of the graft mounted in flow circuit.
(E) Signal generated by anterior and posterior walls of the graft.
and PKH26 (2 µg/mL) or ethidium bromide (3 µg/mL)
and acridine orange (1 µg/mL), and then assessed cell
viability by fluorescence and confocal laser scanning microscopy
(AxioObserver.Z1 and LSM 700, respectively, Carl Zeiss). Cells
were counted in 10 visual fields (x200) per each sample
using ImageJ with the further calculation of total and dead
cell count per 1 mm2. This experiment was performed in
triplicate.
In vivo Implantation
All animal experiments were performed in 6-month-old male
Wistar rats (400–450 g body weight, 12–14 weeks of age, n = 20)
according to all official and ethical requirements. The animals
were allocated in polypropylene cages (five animals per cage)
lined with wood chips and had access to water and food (rat
chow) ad libitum. Throughout the whole time of experiment,
standard conditions of temperature (24± 1◦C), relative humidity
(55± 10%), and 12 h light/dark cycles were carefully maintained,
and the health status of all rats was monitored daily.
After ethylene oxide sterilization, 2 mm inner diameter and
10 mm length PHBV/PCL and PCL grafts with and without
RGD peptides grafts were implanted into rat abdominal aorta
(n = 5 per each group) after the induction of anesthesia with
3% isoflurane. During the surgery, all animals received inhalation
anesthesia with 1.5% isoflurane. Briefly, a midline laparotomy
was performed. After the isolation of the abdominal cavity
with a sterile cloth, intestinal loops were moved to the right
and wrapped in a wet warm cloth. The posterior peritoneal
leaflet was opened along the mesenteric root, and aorta was
mobilized from the level of renal arteries to bifurcation. Then,
aorta was temporarily occluded with two microvascular bulldog
clamps distally from the renal arteries and proximally from
the bifurcation. Aorta and vena cava inferior were occluded in
parallel. Both proximal and distal anastomoses were performed
using Prolene 8–0. Graft was washed between the performances
of these anastomoses. After the implantation, the anterior
abdominal wall was closed layer-by-layer with a blanket suture
(4–0 or 2–0 Vicryl). All procedures were performed using strict
aseptic technique. All the grafts were implanted for 1 month.
After the explantation, grafts with the adjacent aortic tissue
were fixed in 10% (w/v) neutral phosphate buffered formalin
(Electron Microscopy Sciences) during 24 h at 4◦C for the further
histological and immunohistochemical examination.
Histological Examination
Formalin-fixed grafts were dehydrated in isopropanol during 30 h
at 4◦C, rinsed in distilled water, embedded in paraffin (Electron
Microscopy Sciences), sectioned (5 µm), and finally mounted
on glass microscope slides. For a deparaffinization, paraffin-
embedded tissue sections were heated in dry oven at 60◦C for
20 min, immersed in the following reagents: 3x xylene (Electron
Microscopy Sciences) for 10 min, 100%, 95%, 70%, 50%, 30%
ethanol for 1 min each, physiological saline for 2 min, PBS for
2 min, and finally rinsed with tap water.
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For hematoxylin and eosin (H&E) staining, the sections were
immersed in Harris Hematoxylin solution (Electron Microscopy
Sciences) for 1 min, rinsed with tap water, immersed in 1%
aqueous Eosin Y solution (Electron Microscopy Sciences) for
1 min, rinsed with tap water, dehydrated in ascending ethanol
solutions (50%, 70%, 80%, 2x 95%, and 2x 100%), and then
cleared 2x with xylene. For van Gieson staining, the sections
were immersed in Weigert’s working hematoxylin solution
(Electron Microscopy Sciences) for 10 min, rinsed with tap water,
immersed in van Gieson stain (Electron Microscopy Sciences)
for 3 min, rinsed with distilled water, dehydrated in ascending
ethanol solutions (2x 95% and 2x 100%), and cleared 2x with
xylene.
Coverslips were mounted onto a labeled glass slide with
Permount (Electron Microscopy Sciences). After the staining,
sections were evaluated by light microscopy (Axio Imager A1,
Carl Zeiss) in a blinded fashion; three sections per stain were
assessed from each rat (nine sections per rat).
Immunohistochemistry
For immunohistochemical assessment, we used the kit of Leica
Biosystems and rabbit anti-CD31 antibodies (Spring Bioscience)
according to manufacturer’s instructions. Briefly, samples were
boiled in citrate buffer (0.01 M, pH 6.0) for antigen retrieval,
treated by the inhibitor of endogenous peroxidase for 10 min,
and washed twice in phosphate buffer (0.01 M, pH 7.4) for
5 min. For blocking non-specific background staining, we
treated the samples with Protein Block for 10 min with the
further 2x washing in phosphate buffer for 5 min. Then,
we stained the samples with 50 µL of primary anti-CD31
(PECAM-1) antibodies, incubated them in a wet chamber for
1 h, and performed the staining with secondary antibodies.
After the washing in phosphate buffer, we treated samples
with streptavidin-peroxidase conjugate and diaminobenzidine
with the further assessment of the reaction which was stopped
by cold distilled water. Slides were then stained with Mayer’s
Hematoxylin and finally mounted. Native blood vessels and
antibody diluent were used as a positive and negative control,
respectively.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software). A sampling distribution was assessed
by D’Agostino−Pearson test and Kolmogorov–Smirnov test.
FIGURE 2 | Modification of PHBV/PCL and PCL vascular grafts with RGD peptides. (A) Aminolysis reaction scheme between EDA, PHBV, and PCL
monomers. (B) Orange II staining and ninhydrin test demonstrated increased amino group presence in PHBV/PCL and PCL grafts with EDA or RGD peptides
compared to those without, data are represented as mean with standard deviation, ∗∗∗P < 0.001, two-tailed Student’s t-test. (C) Concordance test revealed a
strong correlation between Orange II and ninhydrin assays for PHBV/PCL and PCL grafts with and without EDA treatment. (D) Fourier transform infrared
spectroscopy showed the intensified signal from N–H stretching (around 960 cm−1, black circles) and the increase in amino residues in PHBV/PCL and PCL grafts
with RGD peptides (brown and blue graphs, respectively). Peak around 1045 cm−1 (red circles) corresponds to Si-O-Si stretching, peaks around 1172 and
1240 cm−1 (green circles) correspond to C–O ester stretching, peak around 1720 cm−1 (blue circles) corresponds to C = O aliphatic ester stretching, and peaks
around 2865 and 2941 cm−1 (violet circles) correspond to C–H asymmetric alkyl stretching. (E) Thin layer chromatography (TLC) spots after analyzing hydrolysed (1)
PHBV/PCL, (2) PHBV/PCL/EDA, (3) PHBV/PCL/RGD, and (4) arginine and aspartic acid mixture on chromatographic silica to show the peptide content only in the
RGD modified sample.
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Depending on the distribution, descriptive data were represented
by median and interquartile range (25th and 75th percentiles)
or mean and standard deviation of the mean. Two independent
groups were compared by Mann–Whitney U-test or two-
tailed Student’s t-test. Independent groups numbering three or
more were compared using Kruskal–Wallis test or analysis of
variance (ANOVA), with pairs further compared by Mann–
Whitney U-test or two-tailed Student’s t-test if statistically
significant differences were revealed by Kruskal–Wallis test or
ANOVA, respectively. An adjustment for multiple comparisons
was performed using false discovery rate (FDR). P-values, or
q-values if FDR was applied (q-values are the name given to
the adjusted p-values found using an optimized FDR approach),
≤0.05 were regarded as statistically significant.
RESULTS
PHBV/PCL and PCL Vascular Grafts Can
Be Successfully Modified with RGD
Peptides
Primary amino groups were introduced to the inner surface
of PHBV/PCL and PCL grafts via aminolysis with EDA
(Figure 2A). Orange II treatment detected all primary amines
on the unmodified PHBV/PCL and PCL grafts, after they
were aminolysed, and after the linking reaction with the RGD
peptides. There was an expected and statistically significant
difference between the modified and unmodified polymer
samples (Figure 2B). Ninhydrin testing confirmed the increase
in amino group concentration from unmodified to RGD
modified samples (Figure 2B), and the correlation of the
results between the two tests was significant and strong
(Figure 2C). Concentrations of amino groups were highest in
PHBV/PCL/RGD (14.9 ± 2.9 µM/mm2) and PHBV/PCL/EDA
(14.5 ± 0.5 µM/mm2) with equivalent concentrations on
PCL samples reaching only half (7.55 ± 0.2 µM/mm2). The
colorimetric tests showed the creation of amine groups on
the polymers and provided a method of calculating a sample
concentration of amino groups.
Fourier transform infrared spectroscopy showed that the 2◦
amine peak for RGD-modified PHBV/PCL was stronger than in
non-modified equivalents. Added peptide species on the polymer
were picked up and intensified the signal for the N–H wag
which was visible at approximately 960 cm−1 (Figure 2D). The
characteristic peak for lauric acid at approximately 1730 cm−1
was hidden by the strong ester carbonyl peak presented on
PHBV as well as on PCL. The strong peak at approximately
1170 cm−1 was assigned to C–O–C stretching as ester residues
were abundant in the polymer.
Finally, TLC demonstrated that sample separated into a spot
with its highest and middle point Rf values very similar to those
obtained from the arginine/aspartic acid sample, thus showing
the content in those two amino acids and consequently the LA-
GRGDC-AHex peptide we intended to attach to it (Figure 2E).
FIGURE 3 | PHBV/PCL and PCL vascular grafts with RGD peptides have a distinct morphology. (A) Scanning electron microscopy images of PHBV/PCL
and PCL grafts with and without RGD peptides. (B) Morphological parameters of PHBV/PCL and PCL grafts with and without RGD peptides; quantitative image
analysis revealed a higher mean fiber diameter and mean pore area in PHBV/PCL compared to PCL grafts and in PHBV/PCL grafts with RGD peptides compared to
those without, data are represented as mean with standard deviation, ∗∗∗P < 0.001, two-tailed Student’s t-test.
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FIGURE 4 | PHBV/PCL and PCL vascular grafts with RGD peptides have improved physico-mechanical properties. (A) Modification with RGD peptides
decreased durability of PHBV/PCL and PCL grafts almost to the values of internal mammary artery (IMA). (B) Modification with RGD peptides reduced elasticity of
PHBV/PCL and PCL grafts; however, it was still far from that of IMA. (C) Modification with RGD peptides decreased stiffness of PHBV/PCL grafts but increased
stiffness of PCL grafts; for PCL grafts, stiffness was close to that of IMA. (D) Measurement of compliance found no significant differences for both PHBV/PCL and
PCL grafts with and without RGD peptides. (E) Calculation of stress-strain curve of PHBV/PCL and PCL grafts with and without RGD peptides revealed it is still far
from that of IMA. Data are represented as median with interquartile range, ∗∗P < 0.01, ∗∗∗P < 0.001, Mann–Whitney U-test.
RGD Peptides Alter Porous Structure of
PHBV/PCL and PCL Vascular Grafts
Both PHBV/PCL and PCL grafts had a highly porous structure
with a respective 170–200 and 250–350 µm wall thickness
and homogenous fibers (Figure 3A). Mean fiber diameter and
mean pore area in PHBV/PCL grafts were significantly higher
compared to PCL grafts (2.63 ± 1.14 and 2.06 ± 0.69 µm;
47.13± 63.00 and 23.59± 26.80µm2, respectively). Modification
with RGD peptides significantly decreased mean fiber diameter
and mean pore area in PHBV/PCL grafts but increased mean




PHBV/PCL and PCL Vascular Grafts
Modification of PHBV/PCL and PCL scaffolds with RGD
peptides significantly reduced durability of the scaffolds,
making it similar to IMA (Figure 4A). It also decreased
elasticity of both PHBV/PCL and PCL scaffolds (Figure 4B),
and reduced stiffness of PHBV/PCL scaffolds but increased
stiffness of PCL scaffolds (Figure 4C). However, RGD peptides
had no effect on compliance (Figure 4D) and did not
affect stress-strain curve (Figure 4E). Comparison of both
polymer scaffolds with and without RGD peptides, ePTFE,
SV, and IMA revealed that modification with RGD peptides
made both types of polymer scaffolds more similar to
IMA.
RGD Peptides Increase Viability of
Endothelial Cells Cultured on PHBV/PCL
and PCL Scaffolds
Cell count after 6 days of culture revealed that HUVEC can be
hardly cultured on both PHBV/PCL and PCL scaffolds without
RGD peptides; however, modification of polymer surface with
RGD peptides significantly enhanced endothelial cell viability
(Figures 5A,B). The total number of cells on PHBV/PCL and
PCL scaffolds with RGD peptides was 9.7- and 8.8-fold higher,
respectively, compared to those without RGD peptides whilst the
number of dead cells was similar (Figure 5C).
RGD Peptides Recruit Endothelial Cells
to the Implanted PHBV/PCL and PCL
Vascular Grafts
Histological and immunohistochemical examination 1 month
postimplantation revealed that both PHBV/PCL and PCL grafts
without RGD peptides were occluded and did not contain any
endothelial cells on their inner surface (Figure 6). However, we
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FIGURE 5 | PHBV/PCL and PCL scaffolds with RGD peptides improve cell viability. (A) Fluorescence microscopy showed several-fold increase in total cell
count on PHBV/PCL and PCL scaffolds with RGD peptides in comparison with those without. Nuclei and cytoplasm are stained blue and red, respectively.
(B) Confocal laser scanning microscopy confirmed the results obtained by fluorescence microscopy. Nuclei of the dead cells are stained orange whilst viable cells
are stained green. (C) Quantitative analysis confirmed the results of microscopy analysis, data are represented as median with interquartile range, ∗∗∗P < 0.001,
Mann–Whitney U-test.
FIGURE 6 | Modification of PHBV/PCL and PCL vascular grafts with RGD peptides enhances formation of endothelial cell monolayer. H&E and van
Gieson staining revealed a putative endothelial cell monolayer on PHBV/PCL and PCL grafts with RGD peptides but not on those without; this was further confirmed
by CD31 staining, which identified a monolayer of CD31-positive cells (brown) at the inner surface of both polymer grafts with RGD peptides.
detected an endothelial cell monolayer in PHBV/PCL and PCL
grafts with RGD peptides, which also were completely patent,
thrombus-free, and had no signs of inflammation within the graft
wall.
DISCUSSION
It has been demonstrated that RGD peptides enhanced cell
adhesion as well as cell viability (de Mel et al., 2014). Covalent
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immobilization of RGD peptides on PCL surface led to
an about 11-fold increase in endothelial cell attachment in
comparison with untreated PCL (Gabriel et al., 2006). These
results were further confirmed on another cell lines (Gabriel
et al., 2012). RGD peptides improved haemocompatibility,
cell infiltration, endothelialisation, formation of the smooth
muscle cell layer, and patency of electrospun PCL vascular
grafts implanted into rabbit carotid arteries for 2 and 4 weeks
(Zheng et al., 2012). These results were further confirmed
on PCL vascular grafts prepared by salt leaching (Kang
et al., 2015). Moreover, it was shown that it is in situ
recruitment of endothelial cells and endothelial progenitor
cells but not in vitro endothelialisation that provides patency
of the graft (Kang et al., 2015). Recently, Pontailler et al.
(2015) demonstrated a successful formation of endothelial
cell monolayer and continuous layer of smooth muscle
cells on a poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-4-
hydroxyvalerate) vascular graft modified with RGD peptides in
a rat model of partial inferior vena cava replacement 6 weeks
postimplantation.
Here we showed that modification of PHBV/PCL and PCL
vascular grafts with RGD peptides alters their morphology,
improves physico-mechanical properties, increases endothelial
cell viability, and enhances graft endothelialisation in vivo
1 month postimplantation. PHBV/PCL grafts modified with
RGD peptides had lower mean fiber diameter and pore area;
however, this was opposite for PCL grafts, and it can be
explained by a distinct nature of these polymers. RGD peptides
decreased durability of both PHBV/PCL and PCL to almost
similar to IMA; however, this was not the case for elasticity,
compliance, and stress-strain curve. The results obtained in
the cell culture experiments and in a rat model were similar
for both polymers. To the best of our knowledge, there are
no data regarding modification of PHBV/PCL vascular grafts
with RGD peptides, particularly regarding model of arterial
replacement. In addition, our results confirm those reported for
PCL vascular grafts in the previous studies (Gabriel et al., 2012;
Zheng et al., 2012; Kang et al., 2015) Therefore, modification of
PHBV/PCL and PCL vascular grafts with RGD peptides improves
their physico-mechanical properties and biocompatibility. The
next stage of the research is using larger animal model for
assessment of the bypass graft. We have already chosen the
ovine model, which is the model of choice for the evaluation
of cardiovascular implants in vivo (Rashid et al., 2004).
The anatomic and haemodynamic conditions are sufficiently
analogous to the human situation whilst the long neck region
facilitates easy surgical access to vessels of appropriate size
for implantation. Furthermore, sheep represent a “worst case
model” due to the increased calcium metabolism allowing
for the assessment of degenerative processes of cardiovascular
implants in a relatively short time period (Hoerstrup et al.,
2006).
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